Liefaard, M. C.
van der Voort, A.
van Ramshorst, M. S.
Sanders, J.
Vonk, S.
Horlings, H. M.
Siesling, S.
de Munck, L.
van Leeuwen, A. E.
Kleijn, M.
Mittempergher, L.
Kuilman, M. M.
Glas, A. M.
Wesseling, J.
Lips, E. H.
Sonke, G. S.
Article History
Received: 15 November 2022
Accepted: 25 May 2023
First Online: 19 June 2023
Declarations
:
: This study was approved by the Institutional Research Board of the Netherlands Cancer Institute (CFMPB672). In addition, the review board of the Netherlands Cancer Registry and Statistics Netherlands approved this study and it was conducted in accordance with the Declaration of Helsinki. The TRAIN-2 clinical trial was approved by the medical ethics committee of the Netherlands Cancer Institute, and all participants signed written informed consent before any study-related procedure.
: Not applicable.
: G.S.S. reports institutional research support from Agendia, AstraZeneca, Merck, Novartis, Roche and Seagen and consultancy fees paid to the institute from Biovica and Seagen. H.M.H. reports institutional research support from Roche. M.K., L.M, M.M.K. and A.M.G. are employees of Agendia NV. All other authors have no conflicts of interest to declare.